Tucatinib

Generic Name
Tucatinib
Brand Names
Tukysa
Drug Type
Small Molecule
Chemical Formula
C26H24N8O2
CAS Number
937263-43-9
Unique Ingredient Identifier
234248D0HH
Background

Tucatinib is a kinase inhibitor drug used with trastuzumab and capecitabine in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other ch...

Indication

本品与曲妥珠单抗和卡培他滨联用治疗人类表皮生长因子受体2(HER2)阳性且已出现转移(如脑转移)或无法进行乳房切除术的乳腺癌成人患者，患者应接受过一种或多种抗HER2乳腺癌药物治疗。

Associated Conditions
Breast Cancer, Unresectable Breast Cancer, Wild-type RAS Metastatic Colorectal Cancer, Unresectable RAS Wild Type Colorectal Cancer
Associated Therapies
-
Clinical Trials
Related News

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

First Posted Date
2021-10-25
Last Posted Date
2022-08-18
Lead Sponsor
Silverback Therapeutics
Target Recruit Count
2
Registration Number
NCT05091528
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

First Posted Date
2021-09-30
Last Posted Date
2023-12-29
Lead Sponsor
Gruppo Oncologico del Nord-Ovest
Target Recruit Count
477
Registration Number
NCT05062889
Locations
🇮🇹

Fondazione Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy

🇮🇹

Azienda Ospedaliera Cardinale Giovanni Panico, Tricase, Lecce, Italy

🇮🇹

Ospedale San Donato di Arezzo, Arezzo, Italy

and more 25 locations

Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer

First Posted Date
2021-09-13
Last Posted Date
2024-10-17
Lead Sponsor
UNICANCER
Target Recruit Count
53
Registration Number
NCT05041842
Locations
🇫🇷

Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France

🇫🇷

Centre Francois Baclesse, Caen, France

🇫🇷

Centre Georges François Leclerc, Dijon, France

and more 12 locations

Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.

Phase 1
Withdrawn
Conditions
Breast Cancer Stage IV
Interventions
Drug: Tucatinib
First Posted Date
2021-05-21
Last Posted Date
2023-06-22
Lead Sponsor
Providence Health & Services
Registration Number
NCT04896320
Locations
🇺🇸

Providence Newberg Medical Center, Newberg, Oregon, United States

🇺🇸

Portland Providence Medical Center, Portland, Oregon, United States

🇺🇸

Providence Cancer Institute - Clackamas Clinic, Clackamas, Oregon, United States

and more 1 locations

Tucatinib Together With Pembrolizumab and Trastuzumab

First Posted Date
2021-03-09
Last Posted Date
2024-06-21
Lead Sponsor
Breast Cancer Trials, Australia and New Zealand
Target Recruit Count
57
Registration Number
NCT04789096
Locations
🇦🇺

Peter MacCallum Cancer Centre, Parkville, Victoria, Australia

🇦🇺

Macquarie University, Macquarie Park, New South Wales, Australia

🇦🇺

Nepean Cancer Care Centre, Kingswood, New South Wales, Australia

and more 12 locations

A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)

Phase 2
Active, not recruiting
Conditions
Breast Cancer
Interventions
Drug: Tucatinib
Biological: Trastuzumab
Drug: Capecitabine
First Posted Date
2021-01-25
Last Posted Date
2024-08-09
Lead Sponsor
Pfizer
Target Recruit Count
66
Registration Number
NCT04721977
Locations
🇰🇷

Seoul National University Hospital ( Site 2003), Seoul, Korea, Republic of

🇯🇵

National Cancer Center Hospital ( Site 1003), Tokyo, Japan

🇯🇵

Fukushima Medical University Hospital ( Site 1012), Fukushima, Japan

and more 25 locations

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

First Posted Date
2020-11-17
Last Posted Date
2024-03-07
Lead Sponsor
Genentech, Inc.
Target Recruit Count
252
Registration Number
NCT04632992
Locations
🇺🇸

Kaiser Permanente - San Leandro Medical Center, San Leandro, California, United States

🇺🇸

Ascension St. John Hospital, Detroit, Michigan, United States

🇺🇸

Sarah Cannon Research Institute, Nashville, Tennessee, United States

and more 42 locations

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

First Posted Date
2020-10-08
Last Posted Date
2024-11-13
Lead Sponsor
Seagen Inc.
Target Recruit Count
217
Registration Number
NCT04579380
Locations
🇺🇸

HealthPartners Institute, Saint Louis Park, Minnesota, United States

🇺🇸

Texas Oncology, P.A. - Dallas, Dallas, Texas, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 63 locations

A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

Phase 2
Active, not recruiting
Conditions
HER2 Positive Breast Cancer
Interventions
Drug: tucatinib
Drug: trastuzumab deruxtecan
First Posted Date
2020-09-07
Last Posted Date
2024-08-21
Lead Sponsor
Seagen Inc.
Target Recruit Count
70
Registration Number
NCT04539938
Locations
🇺🇸

UCLA Department of Medicine - Hematology & Oncology, Los Angeles, California, United States

🇺🇸

University of Texas Southwestern Medical Center, Dallas, Texas, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 30 locations

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

First Posted Date
2020-09-04
Last Posted Date
2024-12-13
Lead Sponsor
AstraZeneca
Target Recruit Count
245
Registration Number
NCT04538742
Locations
🇬🇧

Research Site, Buckhurst Hill, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy